Cancer in Jordan

IARC estimates 9,975 new cancer cases and 4,762 cancer deaths in Jordan in 2024; the commonest new cancers are breast, colorectum and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 13 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

9,975

all cancers

Deaths

4,762

all cancers

Incidence rate

111.7

per 100,000, age-standardised

Mortality rate

55.6

per 100,000, age-standardised

Cumulative risk

11.0%

of a cancer by age 74

Population

11,552,882

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Breast	1,866	39.8	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	1,120	13.0	Colorectal cancer
Trachea, bronchus and lung	939	11.2	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Prostate	779	22.4	Prostate cancer
Non-Hodgkin lymphoma	550	5.7	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Thyroid	538	5.5	Thyroid cancer
Leukaemia	489	5.4	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Bladder	366	4.6	Bladder & urothelial cancer
Stomach	325	3.6	Gastric & gastro-oesophageal junction cancer
Pancreas	266	3.2	Pancreatic ductal adenocarcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	793	9.4	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	523	6.2	Colorectal cancer
Breast	510	11.3	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Leukaemia	317	3.6	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Pancreas	260	3.1	Pancreatic ductal adenocarcinoma
Stomach	221	2.6	Gastric & gastro-oesophageal junction cancer
Non-Hodgkin lymphoma	199	2.2	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Prostate	197	5.7	Prostate cancer
Liver and intrahepatic bile ducts	187	2.3	Hepatocellular carcinoma
Brain, central nervous system	172	1.8	Glioma & glioblastoma

Incidence: method 3c, national mortality estimates applied to model-based mortality-to-incidence ratios (registry survival data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Jordan”, in Western Asia (Asia), High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

13 trials in OnCo · 2 recruiting overall

13 trials

Trial			Lead sponsor
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer NCT05894239	Phase 3	Recruiting	Hoffmann-La Roche	192	2026-09-21
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC NCT05491525	Phase 2/3	Recruiting	Urovant Sciences GmbH	38	2026-06-15
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) NCT05296798	Phase 3	Active not recruiting	Hoffmann-La Roche	198	2026-10-02
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer NCT04557059	Phase 3	Active not recruiting	Janssen Pharmaceutica N.V., Belgium	141	2026-09-25
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer NCT05132075	Phase 3	Active not recruiting	Novartis Pharmaceuticals	51	2026-09-25
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L NCT06687369	Phase 3	Active not recruiting	mAbxience Research S.L.	173	2026-09-10
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) NCT05456191	Phase 3	Active not recruiting	Novartis Pharmaceuticals	119	2026-08-26
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases NCT04603807	Phase 3	Active not recruiting	Hoffmann-La Roche	61	2026-08-13
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk NCT06468033	Phase 3	Active not recruiting	PharmaEssentia	73	2026-08-13
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML NCT03591510	Phase 2	Active not recruiting	Novartis Pharmaceuticals	15	2026-07-09
EMPOWER-Lung 1 NCT03088540	Phase 3	Completed	Regeneron Pharmaceuticals	192	2026-06-25
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) NCT05566795	Phase 3	Active not recruiting	Day One Biopharmaceuticals, Inc.	138	2026-05-14
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma NCT06054555	Phase 3	Active not recruiting	Amgen	180	2026-01-12

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Jordan, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Jordan is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

1 institution

King Hussein Cancer Center

1 person

People whose main affiliation in OnCo is an institution or company in Jordan.

Asem Mansour

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Jordan is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Jordan's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Jordan, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Jordan's own sources.

Jordan is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/jo.json; every country: /api/v1/countries.json.